Sarah Shen1, Rory Wolfe2, Catriona A McLean3, Martin Haskett4, John W Kelly4. 1. Victorian Melanoma Service, Alfred Hospital, Victoria, Australia2Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 2. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia. 3. Department of Anatomical Pathology, Alfred Hospital, Victoria, Australia. 4. Victorian Melanoma Service, Alfred Hospital, Victoria, Australia.
Abstract
IMPORTANCE: Mitotic rate is now recognized as having independent prognostic significance in melanoma survival. However, its clinicopathologic associations have not been the focus of any previous study. OBJECTIVE: To identify a set of patient and tumor characteristics associated with high-mitotic-rate melanoma with the aim of facilitating the earlier detection of aggressive primary invasive melanoma. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients from a multidisciplinary melanoma clinic based in a public hospital. A total of 2397 cases from January 2006 to December 2011 were reviewed by the Victorian Melanoma Service, and 1441 patients with 1500 primary invasive melanomas were included in the study. MAIN OUTCOMES AND MEASURES: Mitotic rate was measured as number of mitoses per mm2 and analyzed as ordered categories (0, <1, 1 and <2, 2, 3-4, 5-9, and ≥10) according to patient demographics, phenotypic markers, historical data, tumor presentation, and histopathologic features. RESULTS: Melanomas with higher mitotic rates were more likely to occur in men (odds ratio [OR], 1.5; 95% CI, 1.3-1.8), patients 70 years or older (OR, 2.1; 95% CI, 1.7-2.8), and those with a history of solar keratosis (OR, 1.3; 95% CI, 1.1-1.6). These melanomas occurred more frequently on the head and neck (OR, 1.4; 95% CI, 1.0-1.9) and presented more often as amelanotic (OR, 1.9; 95% CI, 1.4-2.5) and rapidly growing (≥2 mm/mo) lesions (OR, 12.5; 95% CI, 8.4-18.5). An association was seen with the nodular melanoma subtype (vs superficial spreading [reference]) (OR, 2.5; 95% CI, 1.8-3.4), greater tumor thickness (vs ≤1 mm [reference]) (>1-4 mm: OR, 4.5; 95% CI, 3.2-6.1; >4 mm: OR, 12.6; 95% CI, 7.5-21.1), and ulceration (OR, 2.0; 95% CI, 1.5-2.7). These histopathologic features, along with amelanosis and rate of growth, remained as significant associations with high mitotic rate in the overall multivariate analysis. CONCLUSIONS AND RELEVANCE: High-mitotic-rate primary cutaneous melanoma is associated with aggressive histologic features and atypical clinical presentation. It has a predilection for the head and neck region and is more likely to be seen in elderly men with a history of cumulative solar damage who present clinically with rapidly developing disease.
IMPORTANCE: Mitotic rate is now recognized as having independent prognostic significance in melanoma survival. However, its clinicopathologic associations have not been the focus of any previous study. OBJECTIVE: To identify a set of patient and tumor characteristics associated with high-mitotic-rate melanoma with the aim of facilitating the earlier detection of aggressive primary invasive melanoma. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients from a multidisciplinary melanoma clinic based in a public hospital. A total of 2397 cases from January 2006 to December 2011 were reviewed by the Victorian Melanoma Service, and 1441 patients with 1500 primary invasive melanomas were included in the study. MAIN OUTCOMES AND MEASURES: Mitotic rate was measured as number of mitoses per mm2 and analyzed as ordered categories (0, <1, 1 and <2, 2, 3-4, 5-9, and ≥10) according to patient demographics, phenotypic markers, historical data, tumor presentation, and histopathologic features. RESULTS:Melanomas with higher mitotic rates were more likely to occur in men (odds ratio [OR], 1.5; 95% CI, 1.3-1.8), patients 70 years or older (OR, 2.1; 95% CI, 1.7-2.8), and those with a history of solar keratosis (OR, 1.3; 95% CI, 1.1-1.6). These melanomas occurred more frequently on the head and neck (OR, 1.4; 95% CI, 1.0-1.9) and presented more often as amelanotic (OR, 1.9; 95% CI, 1.4-2.5) and rapidly growing (≥2 mm/mo) lesions (OR, 12.5; 95% CI, 8.4-18.5). An association was seen with the nodular melanoma subtype (vs superficial spreading [reference]) (OR, 2.5; 95% CI, 1.8-3.4), greater tumor thickness (vs ≤1 mm [reference]) (>1-4 mm: OR, 4.5; 95% CI, 3.2-6.1; >4 mm: OR, 12.6; 95% CI, 7.5-21.1), and ulceration (OR, 2.0; 95% CI, 1.5-2.7). These histopathologic features, along with amelanosis and rate of growth, remained as significant associations with high mitotic rate in the overall multivariate analysis. CONCLUSIONS AND RELEVANCE: High-mitotic-rate primary cutaneous melanoma is associated with aggressive histologic features and atypical clinical presentation. It has a predilection for the head and neck region and is more likely to be seen in elderly men with a history of cumulative solar damage who present clinically with rapidly developing disease.
Authors: Nicholas J Taylor; Nancy E Thomas; Hoda Anton-Culver; Bruce K Armstrong; Colin B Begg; Klaus J Busam; Anne E Cust; Terence Dwyer; Lynn From; Richard P Gallagher; Stephen B Gruber; Diane E Nishri; Irene Orlow; Stefano Rosso; Alison J Venn; Roberto Zanetti; Marianne Berwick; Peter A Kanetsky Journal: Int J Cancer Date: 2016-05-30 Impact factor: 7.396
Authors: Rachel M Cymerman; Yongzhao Shao; Kun Wang; Yilong Zhang; Era C Murzaku; Lauren A Penn; Iman Osman; David Polsky Journal: J Natl Cancer Inst Date: 2016-05-27 Impact factor: 13.506
Authors: Wen-Qing Li; Eunyoung Cho; Martin A Weinstock; Suyun Li; Meir J Stampfer; Abrar A Qureshi Journal: J Am Acad Dermatol Date: 2019-01-11 Impact factor: 11.527
Authors: Michael Lattanzi; Yesung Lee; Danny Simpson; Una Moran; Farbod Darvishian; Randie H Kim; Eva Hernando; David Polsky; Doug Hanniford; Richard Shapiro; Russell Berman; Anna C Pavlick; Melissa A Wilson; Tomas Kirchhoff; Jeffrey S Weber; Judy Zhong; Iman Osman Journal: J Natl Cancer Inst Date: 2019-02-01 Impact factor: 13.506
Authors: Clio Dessinioti; Niki Dimou; Alan C Geller; Aravella Stergiopoulou; Serigne Lo; Ulrike Keim; Jeffrey E Gershenwald; Lauren E Haydu; Simone Ribero; Pietro Quaglino; Susana Puig; Josep Malvehy; Lidija Kandolf-Sekulovic; Tatjana Radevic; Roland Kaufmann; Laura Meister; Eduardo Nagore; Victor Traves; Grigorios G Champsas; Mihaela Plaka; Brigitte Dreno; Emilie Varey; David Moreno Ramirez; Reinhard Dummer; Joanna Mangana; Axel Hauschild; Friederike Egberts; Ketty Peris; Laura Del Regno; Ana-Maria Forsea; Sabina A Zurac; Ricardo Vieira; Ana Brinca; Iris Zalaudek; Teresa Deinlein; Eleni Linos; Evangelos Evangelou; John F Thompson; Richard A Scolyer; Claus Garbe; Alexander J Stratigos Journal: J Natl Cancer Inst Date: 2019-12-01 Impact factor: 13.506
Authors: Zachary H Hopkins; Ryan P Carlisle; Zachary E Frost; Julia A Curtis; Laura K Ferris; Aaron M Secrest Journal: J Clin Aesthet Dermatol Date: 2021-12
Authors: Julie S Najita; Susan M Swetter; Alan C Geller; Jeffrey E Gershenwald; Marvin Zelen; Sandra J Lee Journal: J Invest Dermatol Date: 2016-05-29 Impact factor: 8.551